Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Mosquito-Borne Chikungunya Virus Can Cause Long-Term Arthritis

Kathy Holliman  |  Issue: September 2018  |  September 20, 2018

“[Although] a high viral load, which may be evidenced by an intense antiviral response, remains to be confirmed as a definite risk factor, population-based studies have shown the aforementioned factors can be used to estimate the degree of severity and duration of chikungunya disease,” Dr. Mahalingam says. Other proposed risk factors, such as female gender and comorbidities, including preexisting rheumatic disease, have not been confirmed.

Complicating the diagnosis for physicians evaluating a patient with chronic symptoms is that “even though anti-CHIKV IgG [immunoglobulin G] antibody levels in the acute phase and the persistence of IgM antibodies appear to be associated with disease activity and harbinger of poor rheumatologic outcome from sparse individual reports, there is no specific biological marker for assessing chronic disease associated with CHIKV infection,” says Dr. Mahalingam.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Chang and colleagues looked at the frequency of chronic joint pain following CHIKV infection in a prospective cohort of 500 patients in Colombia who were clinically diagnosed during the 2014–2015 epidemic. Their research, also published in Arthritis & Rheumatology in April, is the largest observational study in Latin America to describe the incidence of long-term arthritic symptoms after chikungunya infection.2

The study found that 25% of the 485 patients who had serologically confirmed chikungunya infection had persistent joint pain about 20 months later. They were more likely to have had more severe initial symptoms and to suffer greater joint involvement, including the number of joints involved and a duration of initial joint pain of four weeks or longer. They were more likely to report having missed work or school, and to report their normal activities had been affected by the infection. In this study, development of chikungunya arthritis was not related to older age or female gender.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Recognizing Chronic Chikungunya Arthritis

“Returning travelers from these areas may have fever, rash and joint pain, but they often do not make it to the rheumatologist until they have been suffering with arthritic disease for more than a year,” says Dr. Chang. “It is important that the rheumatologist question the patient about when their symptoms first started and whether the initial symptoms were accompanied by fever, rash and travel to an endemic area.

“I think we are probably missing this diagnosis frequently because we are not used to seeing it. Explosive outbreaks continue in the Americas, with a most recent outbreak occurring in Brazil. This would be a good time to keep track of your Brazilian patients who are coming back with joint pain,” she advises.

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:Conditions Tagged with:chikungunyaCHIKV

Related Articles

    Chikungunya: What Every Rheumatologist Needs to Know

    November 2, 2014

    How to spot, diagnose and treat this rapidly spreading mosquito-borne viral illness whose symptoms mimic arthritis

    Chikungunya Virus May Lead to Long-Term Joint Pain

    November 18, 2020

    COVID-19 isn’t the only viral infection on the rise across the globe, so is chikungunya, which can cause arthritis-like symptoms and may lead to long-term joint pain.

    Chikungunya Virus Vaccine Shows Promise in Early Clinical Trial

    April 21, 2020

    NEW YORK (Reuters Health)—A new chikungunya virus-like-particle vaccine appears to be safe and immunogenic, according to results from a phase 2 trial. “The phase 2 safety, tolerability and immunogenicity were similar to the data seen in an earlier phase 1 study,” Grace L. Chen, MD, of the National Institutes of Health Vaccine Research Center, Bethesda,…

    Experimental Drug Combination Curbs Chikungunya Arthritis in Mice

    May 16, 2017

    Doctors have had few options to treat the chronic rheumatoid arthritis-like symptoms associated with chikungunya virus infections beyond over-the-counter pain relievers. A recent study in Science Translational Medicine has spurred new optimism by finding that a combination therapy—the anti-rheumatic drug abatacept paired with a chikungunya-neutralizing monoclonal antibody—abolished acute symptoms in infected mice.1 The strategy must…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences